Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Other Non-Current Assets (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Other Non-Current Assets for 9 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Non-Current Assets fell 8.09% year-over-year to $1.8 million, compared with a TTM value of $1.8 million through Sep 2025, down 8.09%, and an annual FY2024 reading of $119000.0, down 95.65% over the prior year.
  • Other Non-Current Assets was $1.8 million for Q3 2025 at Puma Biotechnology, up from $1.7 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $12.2 million in Q2 2021 and bottomed at $119000.0 in Q4 2024.
  • Average Other Non-Current Assets over 5 years is $2.9 million, with a median of $2.1 million recorded in 2022.
  • The sharpest move saw Other Non-Current Assets skyrocketed 1444.3% in 2021, then plummeted 95.87% in 2022.
  • Year by year, Other Non-Current Assets stood at $12.2 million in 2021, then plummeted by 83.04% to $2.1 million in 2022, then soared by 32.14% to $2.7 million in 2023, then crashed by 95.65% to $119000.0 in 2024, then soared by 1437.82% to $1.8 million in 2025.
  • Business Quant data shows Other Non-Current Assets for PBYI at $1.8 million in Q3 2025, $1.7 million in Q2 2025, and $2.1 million in Q1 2025.